|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dutta R and Mahato RI: Recent advances in
hepatocellular carcinoma therapy. Pharmacol Ther. 173:106–117.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kawaguchi Y, Honda G, Endo I, Cherqui D
and Kokudo N: Current technical issues for surgery of primary liver
cancer. Liver Cancer. 6:51–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lau WY and Lai EC: The current role of
radiofrequency ablation in the management of hepatocellular
carcinoma: A systematic review. Ann Surg. 249:20–25. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shiina S, Tateishi R, Arano T, Uchino K,
Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, et al:
Radiofrequency ablation for hepatocellular carcinoma: 10-year
outcome and prognostic factors. Am J Gastroenterol. 107:569–578.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feng K, Yan J, Li X, Xia F, Ma K, Wang S,
Bie P and Dong J: A randomized controlled trial of radiofrequency
ablation and surgical resection in the treatment of small
hepatocellular carcinoma. J Hepatol. 57:794–802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park W, Chung YH, Kim JA, Jin YJ, Lee D,
Shim JH, Lee D, Kim KM, Lim YS, Lee HC, et al: Recurrences of
hepatocellular carcinoma following complete remission by
transarterial chemoembolization or radiofrequency therapy: Focused
on the recurrence patterns. Hepatol Res. 43:1304–1312. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J,
Tung H, Tso WK, Fan ST and Poon RT: Incomplete ablation after
radiofrequency ablation of hepatocellular carcinoma: Analysis of
risk factors and prognostic factors. Ann Surg Oncol. 15:782–790.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang L, Yin X, Gan YH, Zhang BH, Zhang
JB, Chen Y, Xie XY, Ge NL, Wang YH, Ye SL and Ren ZG:
Radiofrequency ablation following first-line transarterial
chemoembolization for patients with unresectable hepatocellular
carcinoma beyond the Milan criteria. BMC Gastroenterol. 14:112014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang BW, Liang Y, Xia JL, Sun HC, Wang L,
Zhang JB, Tang ZY, Liu KD, Chen J, Xue Q, et al: Biological
characteristics of fluorescent protein-expressing human
hepatocellular carcinoma xenograft model in nude mice. Eur J
Gastroenterol Hepatol. 20:1077–1084. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Tang ZY, Qin LX, Wu XF, Sun HC,
Xue Q and Ye SL: High-dose and long-term therapy with
interferon-alfa inhibits tumor growth and recurrence in nude mice
bearing human hepatocellular carcinoma xenografts with high
metastatic potential. Hepatology. 32:43–48. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, Gao
DM and Ma ZC: Establishment of a metastatic model of human
hepatocellular carcinoma in nude mice via orthotopic implantation
of histologically intact tissues. Int J Cancer. 66:239–243. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bu W, Tang ZY, Sun FX, Ye SL, Liu KD, Xue
Q, Chen J and Gao DM: Effects of matrix metalloproteinase inhibitor
BB-94 on liver cancer growth and metastasis in a patient-like
orthotopic model LCI-D20. Hepatogastroenterology. 45:1056–1061.
1998.PubMed/NCBI
|
|
14
|
Kong J, Kong L, Kong J, Ke S, Gao J, Ding
X, Zheng L, Sun H and Sun W: After insufficient radiofrequency
ablation, tumor-associated endothelial cells exhibit enhanced
angiogenesis and promote invasiveness of residual hepatocellular
carcinoma. J Transl Med. 10:2302012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu M, Xie XH, Xie XY, Xu ZF, Liu GJ, Zheng
YL, Huang GL, Wang W, Zheng SG and Lü MD: Sorafenib suppresses the
rapid progress of hepatocellular carcinoma after insufficient
radiofrequency ablation therapy: An experiment in vivo. Acta
Radiol. 54:199–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ke S, Ding XM, Kong J, Gao J, Wang SH,
Cheng Y and Sun WB: Low temperature of radiofrequency ablation at
the target sites can facilitate rapid progression of residual
hepatic VX2 carcinoma. J Transl Med. 8:732010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakagawa H, Mizukoshi E, Iida N, Terashima
T, Kitahara M, Marukawa Y, Kitamura K, Nakamoto Y, Hiroishi K,
Imawari M and Kaneko S: In vivo immunological antitumor effect of
OK-432-stimulated dendritic cell transfer after radiofrequency
ablation. Cancer Immunol Immunother. 63:347–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Massazza G, Tomasoni A, Lucchini V,
Allavena P, Erba E, Colombo N, Mantovani A, D'Incalci M, Mangioni C
and Giavazzi R: Intraperitoneal and subcutaneous xenografts of
human ovarian carcinoma in nude mice and their potential in
experimental therapy. Int J Cancer. 44:494–500. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Niederberger M, DeLozier-Blanchet CD,
Hedinger CE and Walt H: Differences between subcutaneous and
intraperitoneal forms of three human testicular teratocarcinomas in
nude mice. Cancer. 61:1571–1578. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kasugai H, Osaki Y, Oka H, Kudo M and Seki
T; Osaka Liver Cancer Study Group, : Severe complications of
radiofrequency ablation therapy for hepatocellular carcinoma: An
analysis of 3,891 ablations in 2,614 patients. Oncology. 72 (Suppl
1):S72–S75. 2007. View Article : Google Scholar
|
|
21
|
Koda M, Murawaki Y, Hirooka Y, Kitamoto M,
Ono M, Sakaeda H, Joko K, Sato S, Tamaki K, Yamasaki T, et al:
Complications of radiofrequency ablation for hepatocellular
carcinoma in a multicenter study: An analysis of 16 346 treated
nodules in 13 283 patients. Hepatol Res. 42:1058–1064. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kong J, Kong J, Pan B, Ke S, Dong S, Li X,
Zhou A, Zheng L and Sun WB: Insufficient radiofrequency ablation
promotes angiogenesis of residual hepatocellular carcinoma via
HIF-1α/VEGFA. PLoS One. 7:e372662012. View Article : Google Scholar : PubMed/NCBI
|
